You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.

Open menu

News

Verona’s ensifentrine meets primary endpoint

Verona Pharma has announced its top-line phase 3 ENHANCE-2 trial results evaluating nebulised ensifentrine for the maintenance treatment of chronic obstructive pulmonary disease (COPD).